Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones

    Research output: Contribution to journalArticlepeer-review

    13 Citations (Scopus)


    Chronic heart failure (CHF) is an insulin-resistant (IR) state and the degree of IR is related to disease severity and poor clinical outcome in CHF. IR may be pathophysiologically linked with. Therefore, IR may represent a new target for treatment in CHF. Metformin and thiazolidinediones (TZDs) are effective diabetic therapies that are insulin sensitizers. TZDs are contraindicated in CHF because their use is associated with increased incidence of CHF as a result of their effects on renal sodium reabsorption and vascular permeability. There is evidence to suggest that metformin may be both safe and useful in CHF.
    Original languageEnglish
    Pages (from-to)539-50
    Number of pages12
    JournalHeart Failure Clinics
    Issue number4
    Publication statusPublished - 2012


    Dive into the research topics of 'Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones'. Together they form a unique fingerprint.

    Cite this